Compare Jumia Technologies AG - ADR (JMIA) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Eli Lilly And Co — how do they compare? Jumia Technologies AG - ADR trades at $6.23 (market cap $719.58M), while Eli Lilly And Co trades at $1,220.98 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 1500.9× Jumia Technologies AG - ADR's market cap, and Eli Lilly And Co pays a 0.57% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| JMIA | LLY | |
|---|---|---|
Market Cap | $719.58M | $1.08T |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $1.24K |
52-Week Low | $5.69 | $639.43 |
Enterprise Value | $666.68M | $1.13T |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.245, up 4.08% on the day, amid a bearish technical signal and mixed fundamentals. The company reported revenue of $188.93M for 2025 with a gross profit margin of 54.75%, but net losses persist, and recent earnings have missed expectations. Analyst consensus is strongly bullish with 71.43% buy ratings, while technical indicators show selling pressure.
The outlook hinges on JMIA's path to profitability, targeting Q4 2026 breakeven and 2027 profitability. Risks include high cash burn and competitive pressures, but gross profit growth and strategic partnerships offer potential upside for patient investors focused on the African e-commerce market.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
